Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
25 avr. 2024 08h00 HE
|
Cerevance
Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others Proceeds will advance Cerevance’s first-in-class...
ALX Oncology Realigns Executive Leadership Team
06 sept. 2023 08h00 HE
|
ALX Oncology
Jason Lettmann appointed as Chief Executive OfficerDr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings...
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
19 avr. 2023 09h00 HE
|
Relievant Medsystems, Inc.
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP),...
Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
11 avr. 2023 08h00 HE
|
Catamaran Bio Inc.
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential of TAILWIND® platform to create effective CAR-NK treatments for solid tumors ...
Cerevance Expands Series B Financing with Additional $51 Million
13 févr. 2023 08h30 HE
|
Cerevance
Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023 ...
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
05 janv. 2023 08h00 HE
|
Volta Medical
New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence (AI) Decision-Support Software in improving...
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
03 janv. 2023 16h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance...
Carrick Therapeutics Closes Series C Financing
01 déc. 2022 08h05 HE
|
CARRICK THERAPEUTICS LIMITED
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology pipeline across multiple indications DUBLIN, Ireland and BOSTON, Dec. 01, 2022 (GLOBE...
Cell and Gene Therapy Market Size to Surpass USD 93.78 BN by 2030
30 nov. 2022 07h00 HE
|
Precedence Research
Ottawa, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Latest Research Study on “Cell and Gene Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030”. ...
Hatch commends the governments of Canada and Germany for their leadership in accelerating the global clean energy transition with announcements for the battery metals and hydrogen markets
01 sept. 2022 06h00 HE
|
Hatch Ltd
MISSISSAUGA, Ontario, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Last week, the governments of Canada and Germany came together to discuss two key areas of cooperation as we move towards a net-zero future,...